ECT2 and lung adenocarcinoma: Consistent with our results, analyses of RNA-seq datasets from the TCGA consortium demonstrated that ECT2-S levels were markedly decreased in lung adenocarcinoma, lung squamous carcinoma, and head and neck cancer (Fig. 6c).